All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with MF?
Not difficult at all
0%
Somewhat difficult
0%
Difficult
33%
Very Difficult
66%
3 votes
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with myelofibrosis (MF)?
How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with MF?
In this video, Mascarenhas discusses the analysis from the PERSIST-2 trial (NCT02055781), a randomized phase III study that investigated the safety and efficacy of oral pacritinib compared to the best available therapy to treat MF with thrombocytopenia.
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox